Gout was associated with a 30% higher risk for chronic opioid exposure based on US Veteran's Health Administration data. Patients with gout in the United States are at greater risk for chronic opioid ...
The approval was based on the TRuE-AD3 trial, which evaluated the safety and efficacy of ruxolitinib in pediatric patients aged 2 to 11 years with atopic dermatitis.
HealthDay News — The US Food and Drug Administration (FDA) has approved Opzelura cream 1.5% (ruxolitinib) for children ages 2 to 11 years with atopic dermatitis (AD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback